Dosing regimen for treating PKU with piperidine inhibitor
Summary
The USPTO has published a new patent application (US20260083714A1) detailing a dosing regimen for treating phenylketonuria (PKU) using a piperidine inhibitor of SLC6A19 function. The application was filed on August 25, 2023, by inventors John Peter Throup and Heather Smith Blanchette.
What changed
This document is a patent application published by the USPTO, specifically application US20260083714A1, filed on August 25, 2023. It discloses methods for treating phenylketonuria (PKU) by administering a specific compound, a piperidine inhibitor of SLC6A19 function, or a pharmaceutically acceptable salt thereof.
As a patent application, this document does not impose direct compliance obligations or deadlines on regulated entities. However, it represents potential future intellectual property in the pharmaceutical space for treating PKU. Companies involved in drug development for rare genetic disorders should be aware of this filing as it may impact their research and development strategies or patent landscape.
Source document (simplified)
DOSING REGIMEN FOR TREATING PKU WITH A PIPERIDINE INHIBITOR OF SLC6A19 FUNCTION
Application US20260083714A1 Kind: A1 Mar 26, 2026
Inventors
John Peter Throup, Heather Smith Blanchette
Abstract
Disclosed are methods of treating phenylketonuria, comprising administering to a patient in need thereof an effective amount of the following compound: or a pharmaceutically acceptable salt thereof
CPC Classifications
A61K 31/445
Filing Date
2023-08-25
Application No.
19111597
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.